Match!
Neil McHugh
University of Bath
AutoantibodyPhysical therapyImmunologyPsoriatic arthritisMedicine
441Publications
55H-index
11.1kCitations
What is this?
Publications 465
Newest
#2James B. Lilleker (Salford Royal NHS Foundation Trust)H-Index: 8
Last. Hector Chinoy (Salford Royal NHS Foundation Trust)H-Index: 27
view all 7 authors...
Background: Since first described, our understanding of polymyositis (PM) has evolved substantially. Patients previously diagnosed with PM may now be better described as having an alternative diagnosis, including immune-mediated necrotizing myopathy (IMNM), connective tissue disease overlap myositis (CTD-OM), anti-synthetase syndrome (ASS) or inclusion body myositis (IBM). Objectives: To apply the current understanding of IIM subtypes to retrospectively review the diagnosis of patients classifie...
Source
#1Sarah L. Tansley (University of Bath)H-Index: 10
#2Julia Snowball (University of Bath)H-Index: 12
Last. Neil McHugh (University of Bath)H-Index: 55
view all 8 authors...
BACKGROUND: A myositis-specific autoantibody can now be identified in the majority of patients with myositis. They identify homogeneous patient subgroups and are key tools in developing a personalized approach to disease management. There is substantial clinical interest in exploiting myositis autoantibodies as biomarkers, and consequently, a large number of commercial assays have been developed for their detection. These assays are already in widespread clinical use. In order to better understa...
Source
#1Rachel CharltonH-Index: 11
#2Amelia GreenH-Index: 5
Last. Neil McHugh (University of Bath)H-Index: 55
view all 8 authors...
Background: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that causes pain, stiffness and swelling around the joints. PsA is reported to affect between 10 and 40% of individuals with psoriasis1 and in the majority of patients presents after, or synchronously with, psoriasis onset.2 Osteoarthritis (OA) is a common form of non-inflammatory arthritis related to joint degeneration and typically commences late in the fifth decade. PsA and OA have long been considered two distinct arth...
Source
#1A. Antony (Monash University, Clayton campus)
#2S. Saeed (Royal National Hospital for Rheumatic Diseases)
Last. William Tillett (University of Bath)H-Index: 14
view all 9 authors...
Background: Longitudinal observational data on psoriatic nail dystrophy is scarce, in part due to the lack of a validated outcome measure that is feasible in routine care. The Severity of Nail Psoriasis Score (SNAPS; range 0-40: scored one point each for the presence of pitting, onycholysis, hyperkeratosis and/or severe nail disease# in each fingernail) has face validity and has recently demonstrated feasibility, reliability and cross-sectional construct validity against the modified Nail Psoria...
Source
#1Zoe BetteridgeH-Index: 20
#2Hector ChinoyH-Index: 27
Last. Neil McHughH-Index: 55
view all 10 authors...
OBJECTIVES: To describe the prevalence and clinical associations of autoantibodies to a novel autoantigen, eukaryotic initiation factor 3 (eIF3), detected in idiopathic inflammatory myositis. METHODS: Sera or plasma from 678 PM patients were analysed for autoantigen specificity by radio-labelled protein immunoprecipitation (IPP). Samples immunoprecipitating the same novel autoantigens were further analysed by indirect immunofluorescence and IPP using pre-depleted cell extracts. The autoantigen w...
1 CitationsSource
#1Sarah L. Tansley (University of Bath)H-Index: 10
#2Neil McHugh (University of Bath)H-Index: 55
Source
#2Anna Anthony (Monash University)
Last. William TillettH-Index: 14
view all 7 authors...
Source
#1William Tillett (Royal National Hospital for Rheumatic Diseases)H-Index: 14
#2Adwaye M Rambojun (University of Bath)
Last. Neil McHugh (University of Bath)H-Index: 55
view all 7 authors...
Source
#1Matthew L. ThomasH-Index: 9
#2Gavin ShaddickH-Index: 29
Last. Michal UherH-Index: 4
view all 21 authors...
OBJECTIVE: To investigate whether tumour necrosis factor inhibitor (TNFi) combination therapy with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is more effective for psoriatic arthritis (PsA) and/or improves TNFi drug survival compared to TNFi monotherapy. METHODS: Five PsA biologics cohorts were investigated between 2000 and 2015; the ATTRA registry (Czech Republic), the Swiss Clinical Quality Management PsA registry, the Hellenic Registry of Biologics Therapies (Gre...
Source
#1Amelia Green (University of Bath)H-Index: 5
#2Gavin Shaddick (University of Exeter)H-Index: 29
Last. Neil McHugh (University of Bath)H-Index: 55
view all 8 authors...
BACKGROUND: Psoriatic arthritis (PsA) is a progressive and often destructive joint disease affecting approximately 20% of people with psoriasis. OBJECTIVES: To investigate associations between obesity, changes in body mass index (BMI), alcohol intake and smoking status and the development of PsA in people with psoriasis. METHODS: We undertook a cohort study involving incident cases of psoriasis identified from the U.K. Clinical Practice Research Datalink between 1998 and 2014. The associations b...
5 CitationsSource
12345678910